# Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

> **NCT06600802** · NA · RECRUITING · sponsor: **Centre Jean Perrin** · enrollment: 120 (estimated)

## Conditions studied

- Castration-resistant Metastatic Prostate Cancer
- Treated by 177Lutetium-PSMA-617 (Lu-PSMA)

## Interventions

- **BIOLOGICAL:** Blood samples

## Key facts

- **NCT ID:** NCT06600802
- **Lead sponsor:** Centre Jean Perrin
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-08
- **Primary completion:** 2034-06-30
- **Final completion:** 2034-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06600802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06600802, "Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06600802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*